专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08399015B2 Solid pharmaceutical dosage form 有权
标题翻译：固体药物剂型
公开(公告)号：US08399015B2
公开(公告)日：2013-03-19
申请号：US13240119
申请日：2011-09-22
申请人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Joerg Breitenbach , Laman Alani , Soumojeet Ghosh
发明人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Joerg Breitenbach , Laman Alani , Soumojeet Ghosh
IPC分类号： A61K8/72 , A61K9/20 , A61K9/48 , A61K31/425 , A61K31/505
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
摘要翻译：公开了提供改善的口服生物利用度的固体药物剂型，用于HIV蛋白酶的抑制剂。特别地，剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体，所述药学上可接受的水溶性聚合物的Tg至少为约50 优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。

2. 发明授权

US08333990B2 Solid pharmaceutical dosage form 有权
公开(公告)号：US08333990B2
公开(公告)日：2012-12-18
申请号：US12880766
申请日：2010-09-13
申请人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Joerg Breitenbach , Laman Alani , Soumojeet Ghosh
发明人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Joerg Breitenbach , Laman Alani , Soumojeet Ghosh
IPC分类号： A61K8/72 , A61K9/20 , A61K9/48 , A61K31/425 , A61K31/505
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

3. 发明授权

US08268349B2 Solid pharmaceutical dosage form 有权
标题翻译：固体药物剂型
公开(公告)号：US08268349B2
公开(公告)日：2012-09-18
申请号：US13449958
申请日：2012-04-18
申请人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Joerg Breitenbach , Laman Alani , Soumojeet Ghosh
发明人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Joerg Breitenbach , Laman Alani , Soumojeet Ghosh
IPC分类号： A61K8/72 , A61K9/20 , A61K9/48 , A61K31/425 , A61K31/505
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
摘要翻译：公开了提供改善的口服生物利用度的固体药物剂型，用于HIV蛋白酶的抑制剂。特别地，剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体，所述药学上可接受的水溶性聚合物的Tg至少为约50 优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。

4. 发明授权

US08025899B2 Solid pharmaceutical dosage form 有权
标题翻译：固体药物剂型
公开(公告)号：US08025899B2
公开(公告)日：2011-09-27
申请号：US10925442
申请日：2004-08-25
申请人： Gunther Berndl , Joerg Rosenberg , Bernd Liepold , Joerg Breitenbach , Ulrich Reinhold , Laman Alani , Soumojeet Ghosh
发明人： Gunther Berndl , Joerg Rosenberg , Bernd Liepold , Joerg Breitenbach , Ulrich Reinhold , Laman Alani , Soumojeet Ghosh
IPC分类号： A61K8/72 , A61K9/20 , A61K9/48 , A61K31/425 , A61K31/505
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
摘要翻译：公开了提供改善的口服生物利用度的固体药物剂型，用于HIV蛋白酶的抑制剂。特别地，剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体，所述药学上可接受的水溶性聚合物的Tg至少为约50 优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。

5. 发明授权

US08309613B2 Solid pharmaceutical dosage form 有权
公开(公告)号：US08309613B2
公开(公告)日：2012-11-13
申请号：US12880781
申请日：2010-09-13
申请人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Joerg Breitenbach , Laman Alani , Soumojeet Ghosh
发明人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Joerg Breitenbach , Laman Alani , Soumojeet Ghosh
IPC分类号： A61K8/72 , A61K9/20 , A61K9/48 , A61K31/425 , A61L31/505
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

6. 发明申请

US20110015216A1 Solid Pharmaceutical Dosage Form 有权
标题翻译：固体药物剂型
公开(公告)号：US20110015216A1
公开(公告)日：2011-01-20
申请号：US12880781
申请日：2010-09-13
申请人： Gunther Berndl , Joerg Rosenberg , Bernd Liepold , Joerg Breitenbach , Ulrich Reinhold , Laman Alani , Soumojeet Ghosh
发明人： Gunther Berndl , Joerg Rosenberg , Bernd Liepold , Joerg Breitenbach , Ulrich Reinhold , Laman Alani , Soumojeet Ghosh
IPC分类号： A61K31/513 , A61P31/18
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
摘要翻译：公开了提供改善的口服生物利用度的固体药物剂型，用于HIV蛋白酶的抑制剂。特别地，剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体，所述药学上可接受的水溶性聚合物的Tg至少为约50 优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。

7. 发明申请

US20080181948A1 SOLID PHARMACEUTICAL DOSAGE FORMULATIONS 审中-公开
标题翻译：固体药物制剂
公开(公告)号：US20080181948A1
公开(公告)日：2008-07-31
申请号：US11939640
申请日：2007-11-14
申请人： Gunther Berndl , Joerg Rosenberg , Bernd Liepold , Katja Fastnacht , Tina Jung , Wolfgang Roth , Joerg Breitenbach , John Morris , Cheri E. Klein , Yan Cai , Laman Alani , Soumojeet Ghosh
发明人： Gunther Berndl , Joerg Rosenberg , Bernd Liepold , Katja Fastnacht , Tina Jung , Wolfgang Roth , Joerg Breitenbach , John Morris , Cheri E. Klein , Yan Cai , Laman Alani , Soumojeet Ghosh
IPC分类号： A61K9/28 , A61K31/427 , A61P31/18 , A61K9/107
CPC分类号： A61K31/427 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/2013 , A61K9/2027 , A61K9/2077 , A61K9/2095
摘要： The present invention features solid pharmaceutical dosage formulations comprising ritonavir. As a non-limiting example, a dosage form of the present invention comprises a solid dispersion or solid solution of ritonavir in a matrix, where the matrix comprises at least one water-soluble polymer, such as copovidone, and at least one surfactant, such as polyoxyl 40 hydrogenated castor oil or macrogolglycerol hydroxystearate. Preferably, the solid dispersion or solution does not include, or includes only an insignificant amount of, PEG.
摘要翻译：本发明的特征在于包含利托那韦的固体药物剂型。作为非限制性实例，本发明的剂型包含利托那韦在基质中的固体分散体或固体溶液，其中基质包含至少一种水溶性聚合物如共聚维酮，和至少一种表面活性剂，例如作为聚氧乙烯40氢化蓖麻油或聚乙二醇羟基硬脂酸酯。优选地，固体分散体或溶液不包括或仅包含不显着量的PEG。

8. 发明申请

US20120202838A1 DRUG FORMULATIONS 审中-公开
标题翻译：药物制剂
公开(公告)号：US20120202838A1
公开(公告)日：2012-08-09
申请号：US13289982
申请日：2011-11-04
申请人： Soumojeet Ghosh , Didier Lefebvre , Bryan Wiesner , Joerg Breitenbach
发明人： Soumojeet Ghosh , Didier Lefebvre , Bryan Wiesner , Joerg Breitenbach
IPC分类号： A61K31/485 , A61P25/04
CPC分类号： A61K9/2077 , A61K9/146 , A61K9/2054
摘要： In one embodiment, the present invention relates to abuse-deterrent drug formulations comprise a plurality of discrete domains uniformly dispersed in a pharmaceutically acceptable matrix, wherein said domains have high fracture toughness and comprise at least one polymer and at least one abuse-relevant drug. In another embodiment, the present invention relates to a formulation comprising a plurality of discrete mechanically reinforcing particles uniformly dispersed in a pharmaceutically acceptable matrix, wherein said matrix has high fracture toughness and comprises at least one polymer and at least one active agent, at least one abuse-relevant drug or a combination of at least one active agent and at least one abuse-relevant drug.
摘要翻译：在一个实施方案中，本发明涉及滥用 - 威慑药物制剂包含均匀分散在药学上可接受的基质中的多个离散区域，其中所述结构域具有高断裂韧性并且包含至少一种聚合物和至少一种滥用相关药物。在另一个实施方案中，本发明涉及包含均匀分散在药学上可接受的基质中的多个离散的机械增强颗粒的制剂，其中所述基质具有高断裂韧性，并且包含至少一种聚合物和至少一种活性剂，至少一种滥用相关药物或至少一种活性剂和至少一种滥用相关药物的组合。

9. 发明申请

US20050131054A1 Test system for evaluating the compatibility of biologically active substances with copolymers 有权
标题翻译：用于评估生物活性物质与共聚物的相容性的测试系统
公开(公告)号：US20050131054A1
公开(公告)日：2005-06-16
申请号：US10508483
申请日：2003-03-19
申请人： Joerg Breitenbach , Bernd Liepold
发明人： Joerg Breitenbach , Bernd Liepold
IPC分类号： G01N33/15 , A61K9/14 , A61K47/14 , A61K47/22 , A61K47/32 , C12Q1/00 , A61K31/4025
CPC分类号： A61K9/146 , A61K47/14 , A61K47/22 , Y10T428/31786
摘要： A test solution agent, a test system and a method for evaluating the compatibility of biologically active substances with N-vinylpyrdolidone are disclosed.
摘要翻译：公开了一种测试溶液剂，测试系统和用于评价生物活性物质与N-乙烯基吡啶酮酮的相容性的方法。

10. 发明授权

US08293374B2 Test system for evaluating the compatibility of biologically active substances with copolymers 有权
标题翻译：用于评估生物活性物质与共聚物的相容性的测试系统
公开(公告)号：US08293374B2
公开(公告)日：2012-10-23
申请号：US10508483
申请日：2003-03-19
申请人： Joerg Breitenbach , Bernd Liepold
发明人： Joerg Breitenbach , Bernd Liepold
IPC分类号： B32B27/06 , A61K9/20 , G01N21/00
CPC分类号： A61K9/146 , A61K47/14 , A61K47/22 , Y10T428/31786
摘要： A test solution agent, a test system and a method for evaluating the compatibility of biologically active substances with N-vinylpyrdolidone are disclosed.
摘要翻译：公开了一种测试溶液剂，测试系统和用于评价生物活性物质与N-乙烯基吡啶酮酮的相容性的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式